Barriers to practicing risk reduction strategies among people who inject drugs

Kristina T Phillips, Kristina T Phillips

Abstract

Introduction and aims: People who inject drugs (PWID) engage in practices that put them at risk for various infections and overdose. The primary aim of this study was to examine common barriers to engaging in two risk reduction practices - cleaning one's skin at the injection site and always using new needles to inject - among heroin injectors in Denver, CO.

Method: In 2010, 48 PWIDs were recruited through street outreach and completed a structured interview that included questions on the frequency of specific risk reduction practices (skin cleaning and using new needles) and barriers associated with these practices.

Results: Though many of the reported barriers were similar across the two practices, the most common barriers associated with skin cleaning included being in withdrawal and not being prepared with materials prior to injection. Fear of being arrested and being in withdrawal were most frequently reported for using new needles. Multivariate and t-test analyses demonstrated that individuals who skin cleaned and used new needles more frequently reported less barriers to these practices.

Conclusions: Participants reported a number of barriers to risk reduction, including those that are within the personal control of the injector, barriers that are consequences of addiction or psychological problems, and those that are structural or a function of the risk environment. Statistical analysis found that PWIDs who were more likely to skin clean and use new needles reported less barriers. Addressing barriers when intervening with PWID appears important to increase the success of risk reduction interventions.

Keywords: barriers; harm reduction; heroin; injection drug use; risk reduction.

References

    1. Beletsky L, Grau LE, White E, Bowman S, Heimer R. The roles of law, client race and program visibility in shaping police interference with the operation of US syringe exchange programs. Addiction. 2011;106(2):357–365.
    1. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clinical Infectious Diseases. 2000;30:579–581.
    1. Bluthenthal RN, Malik MR, Grau LE, Singer M, Marshall P, Heimer R the Diffusion of Benefit through Syringe Exchange Study Team. Sterile syringe access conditions and variations in HIV risk among drug injectors in three cities. Addiction. 2004;99(9):1136–1146.
    1. Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction. 2007;102(4):638–646. PMID: 17286637.
    1. Bonar EE, Rosenberg H. Injection drug users’ perceived barriers to using self-initiated harm reduction strategies. Addiction Research and Theory. 2014;22(4):271–278.
    1. Chitwood D, Griffin D, Comerford M, Page J, Trapido E, Lai S, McCoy C. Risk factors for HIV-1 seroconversion among injection drug users: A case control study. American Journal of Public Health. 1995;85:1538–1542.
    1. Colon HM, Finlinson HA, Negron J, Sosa I, Rios-Olivares E, Robles RR. Pilot trial of an intervention aimed at modifying drug preparation practices among injection drug users in Puerto Rico. AIDS and Behavior. 2009;13:523–531.
    1. Compton WM, Horton JC, Cottler LB, Booth RE, Leukefeld CG, Singer M, Spitznagel EL. A multistate trial of pharmacy syringe purchase. Journal of Urban Health. 2004;81:661–670.
    1. Copenhaver MM, Johnson BT, Lee IC, Harman JJ, Carey MP the SHARP Research Team. Behavioral HIV risk reduction among people who inject drugs: Meta-analytic evidence of efficacy. Journal of Substance Abuse Treatment. 2006;31:163–171.
    1. Des Jarlais DC, Friedman SR, Hopkins W. Risk reduction for the Acquired Immune Deficiency Syndrome among intravenous drug users. Annals of Internal Medicine. 1985;103:755–759.
    1. Des Jarlais DC, Hagan H, Arasteh K. Can intranasal drug use reduce HCV infection among injecting drug users? Drug and Alcohol Dependence. 2011;119(3):201–206.
    1. Fraser S, Moore D. Harm reduction and Hepatitis C: On the ethics and politics of prevention and treatment. Addiction Research & Theory. 2011;19(4):375–379.
    1. Friedman SR, Des Jarlais DC, Sotheran JL. AIDS health education for intravenous drug users. Health Education Quarterly. 1986;13(4):383–393.
    1. Friedman SR, Sandoval M, Mateu-Gelabert P, Meylakhs P, Des Jarlais DC. Symbiotic goals and the prevention of blood-borne viruses among injection drug users. Substance Use & Misuse. 2011;46(2–3):307–315.
    1. Gagnon H, Godin G. Psychosocial factors explaining drug users’ intention to use a new syringe at each injection. Addiction Research and Theory. 2009;17(5):481–492.
    1. Gleghorn AA, Corby NH. Injection drug users’ reactions to guidelines for bleach disinfection of needles and syringes: Implications for HIV prevention. Journal of Drug Issues. 1996;26:865–881.
    1. Gordon RJ, Lowy FD. Bacterial infections in drug users. New England Journal of Medicine. 2005;353:1945–1954.
    1. Grund JPC, Friedman SR, Stern LS, Jose B, Neaigus A, Curtis R, Des Jarlais DC. Syringe-mediated drug sharing among injecting drug users: Patterns, social context and implications for transmission of blood-borne pathogens. Social Science & Medicine. 1996;42(5):691–703.
    1. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors. Journal of Substance Abuse Treatment. 2000;19:247–252.
    1. Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA, Hudson SM, Ouellet LJ. Attribution of Hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Journal of Infectious Diseases. 2010;201:378–385.
    1. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health. 2001;91:42–46.
    1. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Moss AR. Hepatitis C Virus seroconversion among young injection drug users: Relationships and risks. Journal of Infectious Diseases. 2002;186:1558–1564.
    1. Hammett TM, Phan S, Gaggin S, Case P, Zaller N, Lutnick A, Des Jarlais DC. Pharmacies as providers of expanded health services for people who inject drugs: A review of laws, policies, and barriers in six countries. BMC Health Services Research. 2014;14:261.
    1. Harm Reduction Coalition. New York: Harm Reduction Coalition; 2012. [accessed April 2015]. Getting off right: A safety manual for injection drug users. Retrieved from .
    1. Heimer R, Khoshnood K, Bigg D, Guydish J, Junge B. Syringe use and reuse: Effects of syringe exchange programs in four cities. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18(Supp 1):S37–S44.
    1. Hughes RA. “When you’re using gear you put HIV to the back of your mind and forget about it”: Constructs of risk. Journal of Psychoactive Drugs. 2004;36:357–366.
    1. Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: A longitudinal study. Journal of Acquired Immune Deficiency Syndromes. 2007;45:108–114.
    1. Kral AH, Anderson R, Flynn NM, Bluthenthal RN. Injection risk behaviors among clients of syringe exchange programs with different syringe dispensation policies. Journal of Acquired Immune Deficiency Syndromes. 2004;37:1307–1312.
    1. Latkin CA, Mandell W, Vlahov D, Knowlton AR, Oziemkowska M, Celentano DD. Self-reported reasons for needle sharing and not carrying bleach among injection drug users in Baltimore, Maryland. The Journal of Drug Issues. 1995;25(4):865–870.
    1. Mateu-Gelabert P, Sandoval M, Meylakhs P, Wendel T, Friedman SR. Strategies to avoid opiate withdrawal: Implications for HCV and HIV risks. International Journal of Drug Policy. 2010;21:179–185.
    1. Newmeyer JA. Why bleach? Fighting AIDS contagion among intravenous drug users: The San Francisco experience. Journal of Psychoactive Drugs. 1988;20(2):159–163.
    1. Nyamathi AM, Lewis C, Leake B, Flaskerud J, Bennett C. Barriers to condom use and needle cleaning among impoverished minority female injection drug users and partners of injection drug users. Public Health Reports. 1995;110:166–172.
    1. Patrick DM, Strathdee SA, Archibald CP, Ofner M, Craib KJ, Cornelisse PG, O'Shaughnessy MV. Determinants of HIV seroconversion in drug users during a period of rising prevalence in Vancouver. International Journal of STD & AIDS. 1997;8:437–445.
    1. Phillips KT, Altman JK, Corsi KF, Stein MD. Development of a risk reduction intervention to reduce bacterial and viral infections for injection drug users. Substance Use & Misuse. 2012;48(102):54–64.
    1. Phillips KT, Stein MD. Risk practices associated with bacterial infections among injection drug users in Denver, Colorado. The American Journal of Drug and Alcohol Abuse. 2010;36:92–97.
    1. Phillips KT, Stein MD, Anderson BJ, Corsi KF. Skin and needle hygiene intervention for injection drug users: Results from a randomized, controlled Stage I pilot trial. Journal of Substance Abuse Treatment. 2012;43:313–321.
    1. Rhodes T. The 'risk environment': A framework for understanding and reducing drug-related harm. International Journal of Drug Policy. 2002;13:85–97.
    1. Rhodes T. Risk environments and drug harms: A social science for harm reduction approach. International Journal of Drug Policy. 2009;20(3):193–201.
    1. Rhodes T, Treloar C. The social production of hepatitis C risk among injecting drug users: A qualitative synthesis. Addiction. 2008;103:1593–1603.
    1. Royer M, Fuller BE, Ober A, Booth RE. HIV and HCV Counseling and Education (C&E) Intervention Training Manual, version 3.0 (NIH Publication No. 93-3580) Bethesda, MD: National Institute on Drug Abuse; 2004.
    1. Ross MW, Wodak A, Stowe A, Gold J. Explanations for sharing injection equipment in injecting drug users and barriers to safer drug use. Addiction. 1994;89(4):73–479.
    1. Sobell LC, Sobell MB. Timeline Followback user's guide: A calendar method for assessing alcohol and drug use. Toronto, Ontario, Canada: Addiction Research Foundation; 1996.
    1. Strathdee SA, Galai N, Safaiean M, Celentano DD, Vlahov D, Johnson L, Nelson KE. Sex differences in risk factors for HIV seroconversion among injection drug users: A 10-year perspective. Archives of Internal Medicine. 2001;161:1281–1288.
    1. Stryker J, Coates TJ, DeCarlo P, Haynes-Sanstad K, Shriver M, Makadon HJ. Prevention of HIV infection: Looking back, looking ahead. Journal of the American Medical Association. 1995;273(14):1143–1148.
    1. Treloar C, Cao W. Barriers to use of needle and syringe programmes in a high drug use area of Sydney, New South Wales. International Journal of Drug Policy. 2005;16:308–315.
    1. Vazan P, Mateu-Gelabert P, Cleland CM, Sandoval M, Friedman SR. Correlates of staying safe behaviors among long-term injection drug users: Psychometric evaluation of the Staying Safe Questionnaire. AIDS and Behavior. 2012;16(6):1472–1481.
    1. Vlahov D, Sullivan M, Astemborski J, Nelson KE. Bacterial infections and skin cleaning prior to injection among intravenous drug users. Public Health Reports. 1992;107:595–598.
    1. Williams AB. Women at risk: An AIDS educational needs assessment. Image: The Journal of Nursing Scholarship. 1991;23:208–213.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner